home / stock / ganx / ganx news

GANX News and Press, Gain Therapeutics Inc. From 03/15/22

Stock Information
Company Name: Gain Therapeutics Inc.
Stock Symbol: GANX
Market: NASDAQ
Website: gaintherapeutics.com
Menu
GANX GANX Quote GANX Short GANX News GANX Articles GANX Message Board
Get GANX Alerts

News, Short Squeeze, Breakout and More Instantly...
GANX - Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson's and Alzheimer's Disease at the AD/PD 2022 Conference

Study results provide additional validation that SEE-Tx platform identifies brain-penetrant small molecules ideally suited for CNS diseases caused by protein misfolding Demonstration of in vitro and in vivo functional efficacy in neurodegenerative disease with GCase causal...
GANX - Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences

- Oppenheimer 32 nd Annual Healthcare Conference - - AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - - Krabbe Translational Research Network Meeting - BETHESDA, M...

GANX - Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022

BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discov...

GANX - Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day

BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with its proprieta...
GANX - Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day

BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery plat...

GANX - Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences

- Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable - - 18 th Annual WORLDSymposium – - AD/PD™ 2022 - BETHESDA, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: ...

GANX - Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference

BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disor...
GANX - Gain Therapeutics announces inducement grants to COO

Gain Therapeutics (NASDAQ:GANX) announced the grant of an option to purchase 200K shares and 200K restricted stock units to COO Matthias Alder. The stock options vest 4+ years, with 1/4th of the shares subject to the option vesting on the first anniversary of Mr. Alder's e...

GANX - Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lyso...

GANX - Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update

BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lyso...
Previous 10 Next 10